Enzyme News and Research

RSS

MPM Capital leads Alnara Pharmaceuticals' $35M Series B venture capital financing

Alnara Pharmaceuticals, Inc., a pharmaceutical company developing non-systemic, orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners. In conjunction with the MPM investment, managing director Ashley Dombkowski, Ph.D., will join Alnara’s board of directors.

28 Jan 2010

Researchers to test newest implant in restoring vision damaged by disease

Researchers trying to restore vision damaged by disease have found promise in a tiny implant that sows seeds of new cells in the eye.

28 Jan 2010

New insight into reprogramming of cells

A discovery by Babraham scientists brings new insight into how cells are reprogrammed and a greater understanding of how the environment, or factors like nutritional signals, can interact with our genes to affect health. As an embryo develops, cells acquire a particular fate, for example becoming a nerve or skin cell. The findings, reported online in the journal Nature, pinpoint a protein called AID as being important for complete cellular reprogramming in mammals.

28 Jan 2010

New research findings may lead to new treatment options for abdominal aortic aneurysms

New research findings from a team at the Providence Heart + Lung Institute at St. Paul's Hospital and the University of British Columbia (UBC) may lead to new treatment options for abdominal aortic aneurysms (AAA) - a potentially fatal disease that currently has no pharmacological treatments.

28 Jan 2010

Patients with NAFLD have higher overall mortality rate, say researchers

Researchers from the Karolinska Institute determined that patients with nonalcoholic fatty liver disease (NAFLD) have a higher overall mortality rate compared with the general population.

28 Jan 2010

MU researcher develops EFdA compound that is more potent than current HIV therapies

With the help of effective drug therapies, HIV patients are living longer, healthier lives. Now, researchers want to improve these drug therapies and develop alternative preventative strategies, such as vaginal gels and creams that contain the same or related compounds used in treatments for people infected with HIV.

27 Jan 2010

Findings provide new insight into factors causing neurodegenerative diseases

Scientists at the Babraham Institute have discovered a novel survival factor whose rapid transport along nerve cells is crucial for keeping them alive. The same factor seems likely to be needed to keep our nerves healthy as we age.

27 Jan 2010

UF researchers work out to find new treatments for Pompe disease

As scientists work to find new treatments for Pompe disease - the devastating genetic "villain" that drives the efforts of the main characters in the new film "Extraordinary Measures" - University of Florida researchers are hopeful that gene therapy will help patients in the late stages of the disease breathe on their own.

27 Jan 2010

Sinobiopharma's solid dosage Perindopril production facility receives Chinese SFDA approval

Sinobiopharma, Inc. is pleased to announce that its production facility for solid dosage Perindopril has passed the required Chinese State Food and Drug Administration (SFDA) inspection and is now approved for production and marketing.

27 Jan 2010

ERYtech Pharma receives ODD for its GRASPA from FDA

ERYtech Pharma announces that FDA has granted an Orphan Drug Designation (ODD) for GRASPA®, the company’s lead product in Acute Lymphoblastic Leukaemia.

27 Jan 2010

Curemark commences CM-AT Phase III autism clinical trial enrollment at ten sites

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that the company is now enrolling patients in Phase III clinical trials for CM-AT, its autism treatment, at ten sites across the country.

27 Jan 2010

Halozyme Therapeutics and BioAtla sign research collaboration agreement

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation.

25 Jan 2010

Study: Warburg effect promotes rapid cell proliferation and tumor growth

A team of scientists led by Professor Adrian Krainer, Ph.D., of Cold Spring Harbor Laboratory has discovered molecular factors in cancer cells that boost the production of an enzyme that helps alter the cells' glucose metabolism. The altered metabolic state, called the Warburg effect, promotes extremely rapid cell proliferation and tumor growth. Adrian Krainer, Ph.D.

23 Jan 2010

NEB's Double Digest Finder and Enzyme Finder tools now available for iPhone and iPod Touch

New England Biolabs' (NEB) popular web tools, Double Digest Finder and Enzyme Finder, are now available for the iPhone™ and iPod® Touch. These tools to help design restriction enzyme experiments are frequently visited on the NEB website, www.neb.com; making them available as free downloads brings their accessibility closer to the bench.

From New England Biolabs 23 Jan 2010

HTDS evaluates business proposal ahead of dividend distribution

Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) subsidiary Slavica Bio Chem recently announced entry into the stem cell bank development. An unsolicited business proposal is currently being evaluated by the company from an obstetrician type medical company. This company is engaged in a treatment for pre-term labor and induction of labor. These symptoms affect millions of people worldwide.

23 Jan 2010

The American Journal of Pathology: Highlights from February 2010 issue

A group led by Dr. Peter Lloyd Jones at the University of Dundee, Dundee, Scotland; the University of Colorado Denver, Aurora, CO; and the University of Pennsylvania, Philadelphia, PA has demonstrated that tenascin-C affects proto-oncogene function in breast cancer. Their report can be found in the February 2010 issue of The American Journal of Pathology.

22 Jan 2010

Postdoctoral scientists receive prestigious award; grants totaling $1.54 million will help in funding innovative projects

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting exceptional early career researchers and innovative cancer research, named 11 new Damon Runyon Fellows at its November 2009 Fellowship Award Committee review.

22 Jan 2010

Researchers identify new therapeutic approach for stroke treatment

For the first time, research led by Youming Lu, PhD, MD, Professor of Neurology and Neuroscience at LSU Health Sciences Center New Orleans School of Medicine, has identified a novel mechanism that may trigger brain damage during stroke and identified a therapeutic approach to block it.

22 Jan 2010

Findings may provide new insights into diabetes; suggest novel targets for drug intervention

The neuropeptide corticotropin-releasing factor (CRF) makes cameo appearances throughout the body, but its leading role is as the opening act in the stress response, jump-starting the process along the hypothalamus-pituitary-adrenal (HPA) axis. Researchers at the Salk Institute for Biological Studies have found that CRF also plays a part in the pancreas, where it increases insulin secretion and promotes the division of the insulin-producing beta cells.

22 Jan 2010

Understanding mechanism of SIRT6 activity may help treat diabetes and cancer

A study investigating how a cellular enzyme affects blood glucose levels in mice provides clues to pathways that may be involved in processes including the regulation of longevity and the proliferation of tumor cells.

22 Jan 2010

Enzyme News and Research

MPM Capital leads Alnara Pharmaceuticals' $35M Series B venture capital financing

Researchers to test newest implant in restoring vision damaged by disease

New insight into reprogramming of cells

New research findings may lead to new treatment options for abdominal aortic aneurysms

Patients with NAFLD have higher overall mortality rate, say researchers

MU researcher develops EFdA compound that is more potent than current HIV therapies

Findings provide new insight into factors causing neurodegenerative diseases

UF researchers work out to find new treatments for Pompe disease

Sinobiopharma's solid dosage Perindopril production facility receives Chinese SFDA approval

ERYtech Pharma receives ODD for its GRASPA from FDA

Curemark commences CM-AT Phase III autism clinical trial enrollment at ten sites

Halozyme Therapeutics and BioAtla sign research collaboration agreement

Study: Warburg effect promotes rapid cell proliferation and tumor growth

NEB's Double Digest Finder and Enzyme Finder tools now available for iPhone and iPod Touch

HTDS evaluates business proposal ahead of dividend distribution

The American Journal of Pathology: Highlights from February 2010 issue

Postdoctoral scientists receive prestigious award; grants totaling $1.54 million will help in funding innovative projects

Researchers identify new therapeutic approach for stroke treatment

Findings may provide new insights into diabetes; suggest novel targets for drug intervention

Understanding mechanism of SIRT6 activity may help treat diabetes and cancer

Biochemistry eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News